News

See you in Cphi Shanghai 2020 from Dec.17th to 19th.

BETA-NICOTINAMIDE MONONUCLEOTIDE CAS Number 1094-61-7 "Nature": Changing a gene can extend life expectancy by 30, Human breakthrough 120 years will become a reality On December 11, researchers from the Sanford Burnham Prebys Medical Research Institute in the United States published a research paper in the international top journal "Nature", saying that as long as the expression of the P62 gene, which is ubiquitous in the body, can be extended by 20% -30%. The discovery may help uncover the secrets of human longevity and help humans find treatments for aging-related diseases. The research team revealed that many studies have shown that cells can extend their life span by enhancing autophagy degradation to recover old, broken and damaged proteins. Autophagy has a strong selectivity, which means that the cells will also adopt a similar method Ways to recycle waste, different types of waste can be transported to the cell's "recycling center". The study found that the P62 gene can transport damaged mitochondria to a recycling center, so the P62 gene is a key substance that affects the life of the organism. The study proved that aging and longevity are closely related to cellular mitochondrial damage. Earlier, scientists gradually realized that the operation of the mitochondrial repair system is closely related to the activity of a long-lived protein family called Sirtuins. Since 2014, David Sinclair's laboratory, a professor of genetics at Harvard Medical School, has further confirmed that the activity of the Sirtuins protein family is closely related to a coenzyme NAD + in the body.NAD + is both an important raw material for the DNA repair system and a key contact factor between the nucleus and the mitochondria. Therefore, by increasing the level of NAD + in the cell to maintain the repair ability of mitochondrial DNA, mitochondrial damage caused by aging can be effectively repaired, which is considered to be a key way to inhibit aging and extend life. In the next few years, Sinclair and Shinichiro Imai's laboratory at the University of Washington independently independently confirmed the ingestion of a naturally occurring NAD + precursor substance BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN, a popular rich man's "longevity" The main ingredient of the drug "Reinvigorator" )can effectively increase the content of NAD + in various organs of the body, thereby improving the DNA repair ability of cells such as mitochondria, and reverse muscle atrophy, improve physical performance, and inhibit cognitive decline caused by aging; Vascular death, protection of cardio-cerebral vascular function, and other aspects have significant anti-aging effects. This is consistent with the core mechanism of altering P62 gene expression and extending lifespan. In the following years, β- NICOTINAMIDE MONONUCLEOTIDE quickly became the focus of research in the field of aging medicine. Harvard University, MIT, Washington University, Keio University and other international top institutions published in Nature, Science, and Cell Nearly a hundred papers of authoritative academic journals such as》 have detailed its efficacy and mechanism of action.And it was confirmed that the increase in NAD + caused by oral BETA-NICOTINAMIDE MONONUCLEOTIDE can extend the life of experimental animals similar to humans by more than 30%. So far, BETA-NICOTINAMIDE MONONUCLEOTIDE has been officially recognized as the world's first scientific research result that has been proven by rigorous scientific experiments to effectively reverse and delay aging and prolong life. Before the introduction of Reinvigorator,BETA-NICOTINAMIDE MONONUCLEOTIDE had been chased by very few wealthy and technical elites who longed for longevity. They heard the wind and tried every means to obtain a small amount of BETA-NICOTINAMIDE MONONUCLEOTIDE from the laboratory through various channels. Nucleotides are for oral consumption. Trump's technology adviser, Silicon Valley venture capitalist, and author of "From 0 to 1" Peter Thiel publicly announced that he would eat a aging inhibitor similar to Reinvigorator almost every day; Bill Gates, the world's richest man, was in an Internet user interaction It has been suggested that many wealthy friends around him are already [artificially prolonging life" by taking products similar to Reinvigoratorβ-NICOTINAMIDE MONONUCLEOTIDE products, and they will consider it themselves; the richest man in China, Li Jiacheng, is taking the previous generation of the product said "feeling 20 years younger" five months later, and immediately decided to invest 25 million Hong Kong dollars to invest in the manufacturer. However, sinceNICOTINAMIDE MONONUCLEOTIDE (the main component of Reinvigorator) were only sold to research institutions as scientific research materials, even if calculated based on the lowest effective dose, the annual cost per person would be as high as 1.56 million yuan. Therefore, β-nicotinamide mononucleotide has become the exclusive benefit of a few of the world's top wealthy and scientists involved in related research, and its road to mass production has been long and arduous. In 2016, Japan's emerging and company took the lead in realizing β-nicotinamide single nucleotide production, but its market price was 20,000 yuan / bottle. In 2018, Herbalmax in the United States reduced the price of β-nicotinamide single nucleotides by more than 90% through advanced enzyme catalysis technology (the pricing of Jingdong, Suning, and Tmall is less than 2,000 yuan), the world's first mature β-nicotinamide single Only Reinvigorator, a nucleotide product, was released. At the end of the same year, after being introduced to China by cross-border e-commerce platforms such as Jingdong Tmall and Suning, Ruiweituo suffered a rush after it was put on the market. With the launch of Reinvigorator, the academic community's research on β-nicotinamide single nucleotides has further heated up. As soon as Rui Wei Tuo went public and was sought after by the wealthy circles, research in the biological sciences academic community continued to advance. In June this year, research results published by the research team of the University of Washington School of Medicine in the journal Cell Metabolism showed that β-nicotinamide single nucleotide expression was increased in mice by injection, leaving the average remaining life length only Two months (equivalent to 6 years in humans) the life length of elderly experimental mice was extended to 4.6 months (that is, 13.8 years in humans), and the remaining life length was doubled. In August 2019, scientists at the Reynolds Geriatrics Research Center in Oklahoma, United States further confirmed: Supplementation of β-nicotinamide mononucleotide to elderly mice can enhance the biosynthesis of NAD + in the body, which can reverse age-related dysfunction of multiple organs including eyes, skeletal muscle and peripheral arteries, and improve and prolong The role of healthy life in aging mice. β-nicotinamide mononucleotide has potential use in the treatment of vascular cognitive impairment caused by aging, and β-nicotinamide single nucleotide-modulated NAD + biosynthetic anti-aging mechanism can be used to develop new drugs To prevent and treat age-related aging diseases. In 1961, American scientist Helfrey proposed that human cells will aging and die when they divide to 50 times, and the cycle of normal cell division is about 2.4 years / time. According to this calculation, the life limit of a person is 120 years. . This is the famous "Helfrey Limit". The iteration of life technology has led people to believe that through artificial interventions such as changing the expression of P62 gene, cell division can be changed, and human life span exceeds the limit of 120 years in Helfrey. By then, everyone's life expectancy will exceed 100 years will become a reality.

A few days ago, the 2020 "Miss America" beauty pageant ended, and Camille Schrier who was 24 years old, won the championship. It is worth mentioning that Schiller is a PhD student in pharmacy, and her talent display link is very "hardcore". Without a swimsuit, nor singing or dancing, Miss America moved a chemistry lab to the final scene. Camille Schrier, dressed in a white lab coat, showed the judges how the hydrogen peroxide catalyzed the decomposition process and surprised the audience. The "catalytic decomposition of hydrogen peroxide" experiment, also often referred to as "elephant toothpaste", is one of the ten most surprising videos of chemical experiments published by Wired magazine in 2009 One. In simple terms, when hydrogen peroxide is mixed with potassium iodide (or other catalysts) and foaming agents, it will accelerate the decomposition rate of hydrogen peroxide. The oxygen released by the reaction will be washed out of the container very quickly, and then wrapped by soapy water to generate a large number of bubbles and gather Become foam gushing like a volcanic eruption. Camille Schrier added pigments to the solution beforehand to create colorful foams that looked interesting and spectacular. Because it is one of the safest and most interesting chemistry experiments, many domestic schools also have demonstrations in chemistry classes ~ In the end, Camille Schrier impressed the judges with a unique talent show, also defeated the other 50 beauties, became the "Miss America" in 2020, and won a prize of $ 50,000 (about RMB 350,000). In an interview, she said she would work to promote drug safety and prevent drug abuse. Camille Schrier has dreamed of participating in beauty pageants since he was a child, becoming the lucky girl with a crown and glory. When she was in high school, she wrote this idea directly on her school's website profile.But as stated in the ins, she can neither sing or dance, she has no talent to perform on the beauty pageant, and only conducts experiments ...... with the encouragement of her mother, she finally decided to move the scientific experiments On the beauty pageant. That's why she came up with this hardcore method to showcase talent ... Camille Schrier said that she acknowledged that her performance was unconventional and was "taking a risk", but the reason why she chose the "catalytic decomposition of hydrogen peroxide" in countless experiments was actually thoughtful: "The talent show is indoors, and there are many audiences. You must ensure safety first, not to catch fire or explode. Secondly, in order for the audience sitting in the last row to see my presentation, I also need it to be a bit visual Effect. Finally, because it is safe, non-toxic, and don`t worry about children imitating ... So, you have what you see. " Because of this wonderful talent show, Camille also played drums in her heart. Before the final, she also sent such a paragraph on the ins to cheer herself up: Confidence is not 'they will like me', Confidence is' I 'll be fine if they don't'. It turns out that "confidence to be a hardcore self" can still win the beauty pageant ~ Scientists lead sexy new trends As the first contestant to pass the "Science" review in the history, and finally won the "Miss America" crown on behalf of Virginia, Camille is also confirming the trajectory of beauty pageants. The beauty pageant that once only looked at measurements and faces has passed formula,Today, hardcore hegemony can also become a beauty pageant. Camille Schrier received a degree in biochemistry and systems biology at the age of 23 and graduated with honors from Virginia Tech. Immediately after, Camille Schrier entered the Virginia Commonwealth University (VCU) School of Pharmacy for a PhD in Pharmacy. After winning the beauty pageant, she also hopes to lead by example and encourage more elementary, junior and high school students to develop a stronger interest in the STEM field (Science Science, Technology, Engineering, Mathematics). "I want every little girl to see that the princess does not always wear a beautiful dress, and sometimes she also wears a lab coat." She also said that in the future she will also work to disseminate knowledge of drug safety to the public and promote the reduction of drug abuse. "I'm not just a person wearing a crown. I have my mission to promote safe medication to more people and make everyone more responsible for their bodies." She hopes that doctors will use the addictive opioids cautiously in the clinic. "Every day, 130 Americans die from opioid overdose; every 8 minutes, parents will give their children the wrong medication ... a lot At times, tragedy can be avoided. "

Runsheng pharmaceutical industry's first drug application On December 12, 2019, Runsheng Pharmaceutical salmeterol-fluticasone Powder Inhaler received CDE approval for clinical development; the indications are: (1) Asthma: This product is used in combination (bronchodilators and inhaled corticosteroids) for regular treatment of reversible obstructive airway diseases, including asthma in adults and children. (2) Chronic obstructive pulmonary disease: This product is suitable for patients with chronic obstructive pulmonary disease, including conventional treatment of chronic bronchitis and emphysema. Earlier in May 2019, Runsheng Pharmaceutical industry submitted its first application, Fluticasone Generic drug, with acceptance numbers (CYHS1900314, CYHS1900315, CYHS1900316). It took 7 months from submission of clinical application to approval of clinical application. Brief introduction of Runsheng Pharmaceutical Co., Ltd. It is Registered in 2014, the original Chongqing Runsheng Technology Co., Ltd. was changed to Runsheng Pharmaceutical Co., Ltd. in November 2018. Located in Shuitu Hi-tech Industrial Park, Beibei District, Chongqing, it is an international enterprise specializing in the development, production and sales of respiratory drugs. Established tiotropium bromide dry powder inhaler, Salmeterol Xinafoate, fluticasone powder inhalation production line. Original GSK of seretide Seretide / Advair (LABA and ICS compound preparations) 2018 global sales performance is about 3.22 billion US dollars; 2017 and 2016 were 4.07 billion and 4.53 billion US dollars. Seretide is a difficult combination of medicinal and mechanical products, consisting of medicines and equipment. The US composition patent expired in 2010, and the dry powder inhalation device patent expired in 2016. The US FDA issued a guideline for the development of Seretide generic drugs in 2013, which provided recommendations on bioequivalence, drug prescription, and inhalation devices. As there is no generic drug on the market, the market of is entirely occupied by the original research pharmaceutical company GSK. According to the sample hospitals in Minei, salmeterol and fluticasone have sales of 1.42 billion yuan in 2017. Seretide Generic drug application company In addition to Runsheng, there are many companies reporting intensively Global Respiratory Drug Market According to IQVIA, global spending on respiratory medicines reached US $ 38.5 billion in 2017, with a compound growth rate of 4.80% from 2012 to 2017. Driven by the deterioration of the global environment, the increase in the prevalence of respiratory diseases, and the approval of new biologics and targeted therapies, the global respiratory drug market will maintain a steady growth.It is estimated that pharmaceutical spending in this area will reach 40-50 billion US dollars in 2022.

Prostate Cancer Drugs: Billions of Abiraterone May Be Purchased 1.Till December 6, 2019, the top three Chinese generic drug abiraterone tablets are currently approved: Hengrui Pharmaceutical's Ai Sente in July 2019; Zhengda Tianqing Pharmaceutical Group's Qing Ke Shu; and Xin Yang from Qingfeng Pharmaceutical (Jiangxi Shanxiang Pharmaceutical) in September 2019. According to relevant data, the prices of the generic drugs learned are in the order of 12,800 yuan / 120 tablets / bottle (250mg), 12,200 yuan / 120 tablets / bottle (250mg), and 11,800 yuan / 120 tablets / bottle (250mg). (Among them, Hengrui Pharmaceutical's investment in research and development of this product is about 39.05 million yuan) In addition, Qilu Pharmaceutical and India's Dr. Reddy`s Abiraterone tablets are also under review. Qilu Pharmaceutical has been approved for listing in the United States (Abbreviated New Drug Application: 212462, QILU PHARM CO LTD, becoming one of the nine generic drug companies in the US market). Two:Original research abiraterone acetate (Zeke) In 2015, the abiraterone acetate (trade name: Zeke) developed by Janssen-Cilag was approved in China, and Xi'an Yangsen was responsible for it in China. On September 25, 2019, Zeke's performance in the Chinese market exceeded 1 billion yuan. Abiraterone acetate is converted into abiraterone in the body, which is an androgen biosynthesis inhibitor that inhibits 17α-hydroxylase / C17,20-lyase (CYP17). Currently approved indications in China: combined with prednisone to treat metastatic castration-resistant prostate cancer (mCRPC) (metastatic castration-resistant prostate cancer); newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate (mHSPC) ( metastatic hormone-sensitive prostate cancer), including no endocrine therapy or endocrine therapy for up to 3 months. It is reported that Johnson & Johnson Abiraterone (foreign trade name: Zytiga) achieved sales of 3.498 billion yuan (peak sales) in FY2018, an increase of 39.6% year-on-year. Johnson & Johnson's 2019Q1 performance report data was 679 million US dollars, down 19.6% year-on-year. The semi-annual report for 2019 shows that Abiraterone sales were 1.377 billion US dollars, down 21.5% year-on-year. In the first three quarters of 2019, Abiraterone's performance was US $ 2.118 billion, a year-on-year decrease of 21.9%. According to relevant data: In 2015, the original research Abiraterone (Zeke) was 36925 yuan 120 tablets / bottle (250mg) at the beginning. In 2017, after the national health insurance negotiations, prices fell by about 53%. At present, the original retail price of Abiraterone (Zeke) is about 16268 yuan / 120 tablets / bottle (250mg) in China. Three:Prostate cancer Prostate cancer is the second most common tumor type in men worldwide, with approximately 1.3 million newly diagnosed patients worldwide in 2018. In China, prostate cancer is the most common genitourinary cancer in men, with an incidence rate of approximately 9.8 per 100,000. The latest data released by the National Cancer Center in 2019 shows that lung cancer is the first male disease, and prostate cancer is the sixth most common disease. The top 10 malignant tumors accounted for about 82.20% of all male malignancies. Four:Suddenly At the end of November 2019, the "Notice on Reporting the Expansion of the Procurement Data Relevant to the Expansion of the National Organizations' Centralized Procurement and Use of Drug Varieties" was spread among pharmaceutical companies. The first to come into view is the oral release of abiraterone. On December 6, 2019, in Shanghai, a new round of national volume procurement work conference was held. It is reported that the policy has undergone new easing. With the approval of the third Chinese abiraterone, the market for generic drugs in exchange for price will become more intense. Perhaps, in 2020, abiraterone will be included in centralized drug procurement. In the future, high-quality generic drugs will benefit domestic patients together with original research drugs!

Pfizer: CDK4/6 new drug palbociclib First in class, will break $5 billion this year Recently, Pfizer released its Q3 financial report for 2019 and disclosed its results for the first three quarters.Pfizer Q3's global performance was 12.68 billion US dollars; the first three quarters of the performance was 39.062 billion US dollars. Pfizer Biopharmaceuticals Group (PBG) - Pfizer Biopharmaceuticals (including innovative drugs, biosimilars, hospitals focused on anti-infectives and sterile injectables), with a performance of $28.887 billion in the first three quarters of 2019.The mature pharmaceutical business unit (composed of patent expired brand drugs and generic drugs) is Upjohn, with a performance of $8.077 billion in the first three quarters of 2019. The consumer health sector's results for the first three quarters of 2019 were $2.098 billion. Pfizer's global product performance in the first three quarters of 2019 Ibrance, the world's first CDK4/6 inhibitor, has a global revenue of $3.677 billion.27% year-on-year growth;The product is expected to exceed the $5 billion mark in FY 2019. It was first approved in the United States in February 2015. After more than four years, it became a super blockbuster. The world's first cyclin-dependent kinase (CDK) 4/6 inhibitor, IBRANCE® ( palbociclib) was approved by the Chinese National Drug Administration (NMPA) on July 31, 2018. IBRANCE® for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, should be combined with aromatase inhibitors as postmenopausal women Initial endocrine therapy. Peirnar 13 vaccine (Prevnar 13) first quarter results of 4.268 billion US dollars Xeljanz (Tofacitinib) had a previous quarterly performance of $1.634 billion. (There are already two generic drugs approved for listing in China, Qilu Pharmaceuticals Tofacitinib, listed in advance!) The first three quarters of Eliquis (Apixaban) were $3.121 billion. (including cooperation with BMS performance and direct sales performance) (Rivaroxaban broke 1.2 billion domestically, a lot of generic drugs for Apixaban to sell!)Other products of pregabalin, atorvastatin, enzalutamide, sunitinib, crizotinib, infliximab, axitinib, sildenafil (Viagra), TNFR-Fc fusion protein The first three quarters were 2.88 billion, 1.506 billion, 594 million, 704 million, 385 million, 446 million, 316 million, 379 million, 1.285 billion. Pfizer China Pfizer's performance in 2019Q3 was 2.195 billion US dollars, down 26% year-on-year. It was mainly affected by the patent cliff of the US market Pregabalin, and the impact of generic drugs started in July 2019.Pfizer's China's third-quarter results only increased by 2%(Vain, which is not included in the volume purchase, sildenafil citrate continues to climb).Pfizer is expected to be in China,Pu Qiang`s performance is compared with 2018,In financial year 2019, there will be an increase in the median to high number (5% to 9%). Pfizer China as a whole grew 42% in 2019 Q3,The main growth comes from the Pfizer China Biopharmaceuticals segment. Growth is driven by products such as palbociclib, tofacitinib, and apixaban. The mid-year report shows that Pfizer`s China`s second quarter results in 2019 fell 20%.The decline was affected by the purchase of 4+7 drugs, and the old products such as Lipitor (Atorvastatin) and Luohuxi (Amlodipine);During the same period, Pfizer China Biopharmaceuticals increased by 26%. Pfizer Strong China's first quarter results in 2019 increased by 13%.

On November 8,Jiangsu Hengrui Pharmaceutical Co., Ltd. announced that it has recently received the "Clinical Trial Notice" approved by the State Drug Administration. The drug Hengrui Medicine is the application for declaration and production, and the National Bureau finally approved the clinical trial. It seems that it is necessary to continue to do clinical trial follow-up production. 1. Name of the drug:Intravenous inhalation powder for Indacaterol Maleate Dosage form: inhalation powder Specification: 150μg (calculated according to C24H28N2O3) Application: Declaration of production Applicant: Jiangsu Hengrui Pharmaceutical Co., Ltd. Reception number: CYHS1900067 2. Other conditions of the drug Indacaterol Maleate inhalation powder is a novel long-acting β2-receptor agonist intended for maintenance therapy in adults with chronic obstructive pulmonary disease (COPD).Inhaled Powder Indacaterol Maleate was first approved by Novartis Pharmaceuticals in November 2009,Specifications are 150μg and 300μg.In July 2011, it was approved by the US FDA and Japan PMDA, and the approved specifications were 75μg and 150μg respectively. Up to now, this product has been approved for listing in more than 50 countries around the world.Upon enquiry, in June 2012, Novartis's inhaled powder of Indacaterol Maleate was approved for import in China. The product name is Anrun, and the specification is 150μg.In January 2019, the company's first inhaled powder of Indacaterol Maleate was invented in the fourth category of chemical registration. After inquiring about the IMS database, global sales of Indacaterol Maleate in 2018 were approximately $111 million, with domestic sales of approximately $307,500. Up to now, the product project has invested R&D expenses of approximately RMB 22.4 million.After inquiring, the drug was reported to be produced for the first time in 2015. It is expected that clinical trials will also be required. Hengrui Pharmaceutical declares production in 6 categories of generic drugs in 2016 and is not expected to be approved.The clinical trial found that Hengrui Medicine completed the human bioequivalence study of the drug for the first time, and the second of Shenzhen Haibin Pharmaceutical completed the BE pre-test and the formal BE test.Inhalation preparations are declared for production, and it is not enough to complete the BE test. It may be necessary to conduct a confirmatory clinical trial.

New medicine for peripheral neuralgia! The first three totals of Tarlige (mirogabalin) were approved for the treatment of peripheral neuropathic pain (PNP) January 17, 2019 / Bio Valley BIOON / -- Daiichi Sankyo, the Japanese pharmaceutical company, recently announced that Tarlige (mirogabalin besylate) 2.5mg, 5mg, 10mg, 15mg tablets have been approved in Japan for the treatment of peripheral neuropathic pain (PNP).In general, an adult patient's initial dose is 5 mg, taken orally twice a day, and then gradually increased by 5 mg to 15 mg at intervals of at least one week The dose can be appropriately adjusted between 10 mg and 15 mg depending on the age and symptoms, and taken orally twice a day for one week. The active pharmaceutical ingredient of Tarlige is mirogabalin, an α2δ ligand created by the first three,By oral administration, the α2δ-1 subunit of voltage-dependent calcium channels (1 and 2) can be preferentially and selectively bound, but the potency is significantly higher than that of pregabalinThese calcium channels are widely present in the nervous system that mediates pain transmission and management in various regions of the body. mirogabalin has unique binding properties and long-acting effects.Mirogabalin belongs to the class of drugs called gabapentinoid, which is the same as gabapentin and pregabalin. The first three submitted a new drug application for Tarlige in February 2018.The drug was approved based on a phase III clinical study in patients with diabetic peripheral neuropathic pain (DPNP) and positive data from a phase III clinical study in patients with postherpetic neuralgia (PHN).Both studies were conducted in Asia, including Japan. In the first three, Tarlige is expected to provide Japanese patients and healthcare professionals with an innovative treatment for peripheral neuropathic pain (PNP).PNP is caused by peripheral nerve damage or dysfunction caused by various causes. Typical PNPs include diabetic PNP (DPNP) and post-herpetic neuralgia (PHN). DPNP and PHN are typical examples of PNP caused by nerve damage.DPNP is a disease that causes neuropathy and numbness in the extremities and is one of the most common long-term complications of diabetes. nerve damage.Symptoms include severe pain, hyperalgesia, numbness, balance and impaired muscle movement, burning and stinging.Pain often worsens at night and can cause sleep disorders.In Japan, it is estimated that there are more than 10 million diabetic patients, and 9-22% of patients report DPNP. The onset of herpes zoster is caused by a decrease in immunity to the varicella-band acne virus, which forms a latent infection in the ganglion .In PHN, even after the cure for herpes zoster, the burning pain or the pain that penetrates the body like electricity still exists. The disease is considered to be a kind of intractable pain, which can cause muscle weakness and can cause paralysis in rare cases.In Japan, between 500,000 and 600,000 people suffer from herpes zoster every year, and 10-25% of them suffer from PHN.

We will go to attend CPhi worldwide 2019 CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 42,000 visiting pharma professionals over three days. 2,500+ exhibitors from 153 countries gather at the event to network and take advantage of more than 150 free industry seminars. Every sector of the pharmaceutical market is represented under one roof, this year in Frankfurt. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends. The exhibition showcases cover the whole spectrum of pharmaceutical manufacturing and ingredients sourcing, offering products and services that cover the entire supply chain. CPhI Worldwide: for pharmaceutical ingredients ICSE: for outsourcing solution providers, contract manufacturing and services InnoPack: for pharmaceutical packaging and drug delivery systems P-MEC: for pharmaceutical machinery, technology and equipment Finished Dosage Formulation (FDF): for every aspect of the finished dosage supply chain

CPhi China 2019 will be hold on June 18th to 20th in Shanghai, Our booth is at E7A96. CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your One-stop Shop pharma platform in Asia.

2017 Nobel Prize for Chemistry announced in Sweden on October 4 local time.The Royal Swedish Academy of Sciences announced that this year's Nobel Prize for Chemistry awarded to Jacques Dubochet, a scientist at the University of Lausanne in Switzerland; Joachim Frank, a scientist at the Columbia University, USA and Richard Henderson,a scientist at MRC Laboratory of Molecular Biology,UK.They created the technology of Cryo-Electron Microscopy which can determination the high-resolution structural of biomolecules in solution.

Cardiovascular disease, also known as circulatory disease, is a series of diseases involving the circulatory system. The circulatory system refers to organs and tissues that carry blood in the human body, mainly including the heart, blood vessels (arteries, veins, microvessels), which can be subdivided into acute And chronic, are generally associated with arteriosclerosis. Anti-Cardiovascular treatment Maintain a balance of mind Emotional heart and cerebrovascular disease is taboo, coronary heart disease, high blood lipids in particular to relax the mind, do not let mood ups and downs too much. Appropriate exercise Cardiovascular and cerebrovascular patients are not unable to exercise, but to exercise properly, reduce the amount of exercise can also cause slow blood flow, elevated blood lipids. Reasonable arrangements for exercise time and control of good exercise. Winter to wait for the sun to rise after the exercise, this time, the temperature rise, to avoid the body suddenly by the cold stimulation and disease. Air anion therapy Blood in the normal red blood cells, colloidal particles with negative charge, they are mutually exclusive, to maintain a certain distance, and the aging of the red blood cells as the electronic competition, with a positive charge, due to positive and negative absorption, the red blood cells condensed into groups The Negative ions can effectively repair the aging cell membrane potential, prompting it to become a normal negatively charged cells, negative negative repulsion to effectively reduce blood viscosity, so that erythrocyte sedimentation rate. At the same time anion can strengthen the blood gelatinous particles in their own negative polar trend, the plasma protein colloid stability increased, to maintain the normal blood health status. other Active treatment of existing cardiovascular and cerebrovascular diseases. Choose a healthy eating plan. The food you eat can decrease your risk of heart disease and stroke. Anti-Cardiovascular Prevention Choose foods low in saturated fat, trans fat, and sodium. As part of a healthy diet, eat plenty of fruits and vegetables, fiber-rich whole grains, fish (preferably oily fish-at least twice per week), nuts, legumes and seeds and try eating some meals without meat. Select lower fat dairy products and poultry (skinless). Limit sugar-sweetened beverages and red meat. If you choose to eat meat, select the leanest cuts available. Be physically active. You can slowly work up to at least 2½ hours (150 minutes) of moderate-intensity aerobic physical activity (e.g., brisk walking) every week or 1 hour and 15 minutes (75 minutes) of vigorous intensity aerobic physical activity (e.g., jogging, running) or a combination of both every week. Learn the American Heart Association's Guidelines for Physical Activity in Adults and in Kids. Additionally, on 2 or more days a week you need muscle-strengthening activities that work all major muscle groups (legs, hips, back, abdomen, chest shoulders, and arms). Children should get at least 60 minutes of activity every day. It's never too early or too late to learn the warning signs of a heart attack and stroke. Not everyone experiences sudden numbness with a stroke or severe chest pain with a heart attack. And heart attack symptoms in women can be different than men. The most influential risk factor for cardiovascular disease is age – the older you are, the greater your risk. The second is your genetic make-up. Although everyone is excited by the scientific progress in genomics research, conclusive gene tests are still in their infancy. But, as I tell our medical students, [A good family history is a poor man`s gene test." We have long known that if your parents, grandparents, or other relatives were afflicted with or died of heart disease, diabetes or stroke, your risk is much greater. Don`t smoke or expose yourself to second-hand smoke. Stress contributes to cardiovascular disease and, if severe, can cause a heart attack or sudden death. There are plenty of options that help reduce stress, such as regular exercise, adequate sleep, striving for a good marriage, laughing, volunteering or attending religious services. Watching TV generally does not relieve, but can aggravate stress. Also, try to avoid situations and people who make you anxious or angry.

We are looking for purchase Nebivolol Intermediate :6-Fluorochromane-2-carboxylic acid CAS 99199-60-7, Purity NLT 99%, If you are able to supply this intermediate, Pls contact us asap. 0576-88869393

Pls. visit us at CPhI Shanghai Booth W5A56during June.24th to26th,2016.

VOLSEN IS ATTENDING CPHI INDIA 2015 CPhI & P-MEC India is the country's largest and leading pharma event. As the pharma industry is increasingly looking towards India for high quality, low cost pharma solutions, this event is the perfect place for companies to pick up on the latest trends and innovations the market has to offer. Meet the movers and shakers in India's pharma machinery, technology, ingredients, outsourcing and biopharma industry for a competitive advantage that will help grow your business.

According to the active ingredient of the special Chinese herbal medicine, the active ingredient is obviously different. Since the API is used in almost all of the ingredients in different proportions, the quality of the raw material for the supplier, etc.. By poor quality, this means that the intensity of the API is lower than it should be. This will automatically lead to the full characterization of the resulting herb that does not bind the active pharmaceutical ingredients. High quality is essential When with the raw material suppliers, must ensure that the high quality of material. In addition, documents, regulations compliance, storage of APIs and packaging, labeling, re packaging, release and production should be in accordance with the standards set by FDA. Keeping a secret is the key to the customer, and the supplier must maintain complete confidentiality and deal with their customers. Suppliers should have a suitable system to accept or reject all intermediate materials, raw materials, labels or packaging materials according to their discretion. All production records must be thoroughly evaluated in order to identify all important process steps to be followed. Only in this way, should the active drug ingredients be released.

Supplementary material benefit Some of the active ingredients of the drug are unknown, and therefore require additional material, which can produce the desired effect in conjunction with the work of API. For example, in the case of a medicinal herb, the API is usually a mixture of several compounds and substances, which are activated and act on a combination of the whole body. Thus, in this case, the active drug ingredient is not a singular substance, but several herbs and ingredients of the apex. API power Manufacturers typically use a certain standard and computational benchmark to determine the relative strength of the drug or drug within the active pharmaceutical ingredient. However, the standard of API of the advantages of the method is different from one brand to another. Although there is a manufacturer can use a certain standard to evaluate the strength of raw materials, other manufacturers can use different standards.

Also known as the raw material, active pharmaceutical ingredients of any drug, which is active. Therefore, depending on the dose, the reaction and the results are different. Some drugs are made up of a drug. Drug ingredients Any medicine is made up of 2 parts or components. The first one is the actual API or active ingredient, which is the central ingredient. The two is the vehicle as everyone knows. This is a substance in a drug or tablet. If it is in the pulp, then the liquid material has been used. As a result, the material appears to have an active or inert substance in the active substance of the drug, which means that the effect of the drug is expected to produce the desired effect.

Our New drug CAL-101(idelalisib) is in bulk stock! CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks Fc?R1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM [1]. CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival [2]. AL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL) [3]. We are availabe for several related Intermediates 1) CAS 385-02-4,2-Fluoro-6-nitrobenzoic acid 2) CAS 870281-83-7,2-Fluoro-6-nitro-N-phenylbenzamide 3) CAS 870281-84-8,(S)-([1-(2-fluoro-6-nitro-benzoyl)-phenyl-aMinocarbonyl]-propyl)-carbaMic acid tert-butyl ester 4) CAS 870281-85-9,(S)-tert-butyl (1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbaMate 5) CAS 870281-86-0,(S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 6) CAS 870281-82-6,CAL-101 7) CAS 767-69-1,6-Bromopurine

CPhi China 2015 Jun.24 to Jun.26, Booth No. T1A30